Differential pricing of drugs: a role for cost-effectiveness analysis?

被引：24

作者：

Lopert, R ^{[1
]}

Lang, DL ^{[1
]}

Hill, SR ^{[1
]}

Henry, DA ^{[1
]}

机构：

[1] Univ Newcastle, Fac Hlth, Sch Med Practice & Populat Hlth, WHO Collaborating Ctr Training Pharmacol & Rat Dr, Newcastle, NSW 2308, Australia

来源：

LANCET | 2002年 / 359卷 / 9323期

关键词：

D O I：

10.1016/S0140-6736(02)08911-0

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Internationally, the high costs of pharmaceutical products limit access to treatment. The principle of differential pricing is that drug prices should vary according to some measure of affordability. How differential prices should be determined is, however, unclear. Here we describe a method whereby differential prices for essential drugs could be derived in countries of variable national wealth, and, using angiotensin-converting enzyme inhibitors provide an example of how the process might work. Indicative prices for drugs can be derived by cost-effectiveness analysis that incorporates a measure of national wealth, Such prices could be used internationally as a basis of differential price negotiations.

引用

页码：2105 / 2107

页数：3

共 19 条

[1]

Baladi JF, 1998, HEALTH ECON, V7, P221, DOI 10.1002/(SICI)1099-1050(199805)7:3<221::AID-HEC341>3.0.CO

[2]

2-N

[3] Public health - HIV/AIDS treatment for millions [J].